Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Structure and dynamics of the M3 muscarinic acetylcholine receptor.

Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, Rosemond E, Green HF, Liu T, Chae PS, Dror RO, Shaw DE, Weis WI, Wess J, Kobilka BK.

Nature. 2012 Feb 22;482(7386):552-6. doi: 10.1038/nature10867.

2.

Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development.

Kruse AC, Hu J, Kobilka BK, Wess J.

Curr Opin Pharmacol. 2014 Jun;16:24-30. doi: 10.1016/j.coph.2014.02.006. Epub 2014 Mar 21. Review.

3.

Accelerated molecular dynamics simulations of ligand binding to a muscarinic G-protein-coupled receptor.

Kappel K, Miao Y, McCammon JA.

Q Rev Biophys. 2015 Nov;48(4):479-87. doi: 10.1017/S0033583515000153. Review.

4.

Crystal structures of the M1 and M4 muscarinic acetylcholine receptors.

Thal DM, Sun B, Feng D, Nawaratne V, Leach K, Felder CC, Bures MG, Evans DA, Weis WI, Bachhawat P, Kobilka TS, Sexton PM, Kobilka BK, Christopoulos A.

Nature. 2016 Mar 17;531(7594):335-40. doi: 10.1038/nature17188. Epub 2016 Mar 9.

5.

Novel insights into M3 muscarinic acetylcholine receptor physiology and structure.

Kruse AC, Li J, Hu J, Kobilka BK, Wess J.

J Mol Neurosci. 2014 Jul;53(3):316-23. doi: 10.1007/s12031-013-0127-0. Epub 2013 Sep 26. Review.

6.

Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.

Schober DA, Croy CH, Xiao H, Christopoulos A, Felder CC.

Mol Pharmacol. 2014 Jul;86(1):116-23. doi: 10.1124/mol.114.091785. Epub 2014 May 7.

7.

Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist.

Villetti G, Pastore F, Bergamaschi M, Bassani F, Bolzoni PT, Battipaglia L, Amari G, Rizzi A, Delcanale M, Volta R, Cenacchi V, Cacciani F, Zaniboni M, Berti F, Rossoni G, Harrison S, Petrillo P, Santoro E, Scudellaro R, Mannini F, Geppetti PA, Razzetti R, Patacchini R, Civelli M.

J Pharmacol Exp Ther. 2010 Dec;335(3):622-35. doi: 10.1124/jpet.110.170035. Epub 2010 Aug 30.

8.

Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist.

Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Kobilka BK, Haga T, Kobayashi T.

Nature. 2012 Jan 25;482(7386):547-51. doi: 10.1038/nature10753.

9.

Allosteric effects of sodium ion binding on activation of the m3 muscarinic g-protein-coupled receptor.

Miao Y, Caliman AD, McCammon JA.

Biophys J. 2015 Apr 7;108(7):1796-806. doi: 10.1016/j.bpj.2015.03.003.

10.

Ligand-specific changes in M3 muscarinic acetylcholine receptor structure detected by a disulfide scanning strategy.

Li JH, Hamdan FF, Kim SK, Jacobson KA, Zhang X, Han SJ, Wess J.

Biochemistry. 2008 Mar 4;47(9):2776-88. doi: 10.1021/bi7019113. Epub 2008 Feb 5.

PMID:
18247581
11.

Structural determinants for the interactions between muscarinic toxin 7 and muscarinic acetylcholine receptors.

Xu J, Zhao H, Zheng Z, Wang Y, Niu Y, Wang H, Xu J, Lu Y, Chen H.

J Mol Recognit. 2015 Apr;28(4):239-52. doi: 10.1002/jmr.2438. Epub 2015 Feb 12.

PMID:
25683330
12.
13.

Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae.

Stewart GD, Sexton PM, Christopoulos A.

Mol Pharmacol. 2010 Aug;78(2):205-14. doi: 10.1124/mol.110.064253. Epub 2010 May 13.

14.
15.

The molecular basis of oligomeric organization of the human M3 muscarinic acetylcholine receptor.

Liste MJ, Caltabiano G, Ward RJ, Alvarez-Curto E, Marsango S, Milligan G.

Mol Pharmacol. 2015 Jun;87(6):936-53. doi: 10.1124/mol.114.096925. Epub 2015 Mar 13.

16.

Structural Characteristics of the Allosteric Binding Site Represent a Key to Subtype Selective Modulators of Muscarinic Acetylcholine Receptors.

Bermudez M, Rakers C, Wolber G.

Mol Inform. 2015 Aug;34(8):526-30. doi: 10.1002/minf.201500025. Epub 2015 Jul 1.

PMID:
27490498
18.

Novel insights into muscarinic acetylcholine receptor function using gene targeting technology.

Wess J.

Trends Pharmacol Sci. 2003 Aug;24(8):414-20. Review.

PMID:
12915051
19.

M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding.

Keller M, Tränkle C, She X, Pegoli A, Bernhardt G, Buschauer A, Read RW.

Bioorg Med Chem. 2015 Jul 15;23(14):3970-90. doi: 10.1016/j.bmc.2015.01.015. Epub 2015 Jan 14.

PMID:
25650309
20.

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.

Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ.

J Pharmacol Exp Ther. 2012 Nov;343(2):520-8. doi: 10.1124/jpet.112.194456. Epub 2012 Aug 1.

Supplemental Content

Support Center